Weekly Research Analysts’ Ratings Changes for Medtronic (MDT)

Several brokerages have updated their recommendations and price targets on shares of Medtronic (NYSE: MDT) in the last few weeks:

• 9/17/2026 – Medtronic had its “buy” rating reaffirmed by Needham & Company LLC.
• 9/5/2026 – Medtronic was downgraded by Wall Street Zen from “buy” to “hold”.
• 9/4/2026 – Medtronic was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 9/3/2026 – Medtronic had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $92.00 price target on the stock.
• 9/3/2026 – Medtronic had its price target raised by UBS Group AG from $100.00 to $110.00. They now have a “buy” rating on the stock.
• 9/2/2026 – Medtronic was given a new $115.00 price target by Mizuho.
• 9/2/2026 – Medtronic had its price target raised by Bank of America Corporation from $95.00 to $110.00. They now have a “buy” rating on the stock.
• 9/2/2026 – Medtronic had its price target raised by Wells Fargo & Company from $102.00 to $104.00. They now have an “overweight” rating on the stock.
• 9/2/2026 – Medtronic had its “hold” rating reaffirmed by Truist Financial Corporation. They now have a $99.00 price target on the stock, up from $86.00.
• 9/2/2026 – Medtronic had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $118.00 price target on the stock.
• 9/2/2026 – Medtronic had its price target raised by Robert W. Baird from $91.00 to $100.00. They now have a “neutral” rating on the stock.
• 9/2/2026 – Medtronic had its price target raised by Stifel Nicolaus from $80.00 to $95.00. They now have a “hold” rating on the stock.
• 9/1/2026 – Medtronic had its price target raised by BTIG Research from $91.00 to $100.00. They now have a “buy” rating on the stock.
• 8/28/2026 – Medtronic had its price target raised by TD Cowen from $100.00 to $110.00. They now have a “buy” rating on the stock.
• 8/27/2026 – Medtronic had its price target raised by Needham & Company LLC from $101.00 to $114.00. They now have a “buy” rating on the stock.
• 8/18/2026 – Medtronic had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 8/18/2026 – Medtronic had its “buy” rating reaffirmed by BTIG Research. They now have a $91.00 price target on the stock.
• 8/10/2026 – Medtronic had its “neutral” rating reaffirmed by Piper Sandler.
• 7/28/2026 – Medtronic was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $100.00 price target on the stock, up from $85.00.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Kiil sold 1,483 shares of the business’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the sale, the executive vice president owned 42,186 shares in the company, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.27% of the company’s stock.

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.